Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Melanoma and Angiogenesis

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3839
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Melanoma and Angiogenesis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Angiogenesis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Melanoma and Angiogenesis.

    To find out more about Triple Analysis: Lymphoma, Melanoma and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Melanoma and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part III: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

This Report Includes the Following Companies:
3SBio
4SC
AB Science
Abbott
AbbVie
Abiogen
Acceleron Pharma
Access
Actelion
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Agennix
Agenus
Aida Pharmaceuticals
Alfa Wassermann
Alfacell
Allos Therapeutics
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Arana Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
Bayer
Benitec
Bio-Medisinsk Innovasjon
BioAlliance Pharma
BioAxone
Biocad
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biokine Therapeutics
Biolex
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Borean Pharma
Bristol-Myers Squibb
BTG
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celltrion
Celtic Pharma
Cephalon
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CSL
Cue Biotech
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytochroma
Cytokinetics
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DNAVEC
Dong-A
Dr Reddy’s
Dyax
Dynavax Technologies
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Epizyme
Exelixis
ExonHit Therapeutics
Favrille
Five Prime Therapeutics
Flamel Technologies
Forma Therapeutics
GammaCan
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Gradalis
Green Cross
Hayashibara
Heber Biotec
HemaQuest
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inotek
Inovio
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Kalypsys
Karus Therapeutics
Karyon-CTT
Kiadis
Kinex
Kirin Pharma
Kissei
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
MAT Biopharma
Meda
MediGene
MedImmune
Medisyn Technologies
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Morvus Technology
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NewSouth Innovations
NIH
Non-industrial source
Novartis
Novelix
Novogen
Noxxon
Nycomed Pharma
Oasmia
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Pacific Biotech
Patrys
PBL Therapeutics
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaMar
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Progen
ProNAi Therapeutics
Protein Sciences
Protgen
PTC Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sareum
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Shionogi
Shire
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Spear Therapeutics
Spirogen
SRI International
Stainwei Biotech
Sunesis
SuperGen
SuppreMol
Swedish Orphan Biovitrum
Switch Pharma
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
to-BBB
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UCB
Vaccinex
VBL Therapeutics
Vectura
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
WntResearch
XBiotech
Xencor
Xerion
Yakult Honsha
York Pharma
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
A6
ABT-510
AEB071
aflibercept
agatolimod
aldesleukin
alemtuzumab
ALT-801
AMG-386
amrubicin hydrochloride
Angiozyme
apatinib
APO-866
ARQ-197
ARRY-438162
astuprotimut-r
atrasentan
Auto TAG vaccine
axitinib
bardoxolone methyl
belinostat
bevacizumab
bexarotene
BIBF-1120
BMS-663513
BMS-690514
BMS-936558
bortezomib
brentuximab vedotin
brivanib alaninate
Buparlisib
Cabozantinib
CB-10-01
cediranib
cilengitide
cladribine
cositecan
CT-011
dasatinib
decitabine
denenicokin
denileukin diftitox
DI-17E6
dinaciclib
dovitinib lactate
E-7820
E7449
elliptinium acetate
EMD-273063
endostatin
ENMD-2076
entinostat
enzastaurin hydrochloride
epirubicin
everolimus
Exherin
foretinib
fosbretabulin tromethamine
fresolimumab
galiximab
ganetespib
ganitumab
gefitinib
glembatumumab vedotin
GliaAtak
golvatinib
GSK-1120212
GSK-2118436
GT-111
GV-1001
GVAX
HBP-347
Hi-8 MEL
histamine dihydrochloride
ibritumomab tiuxetan
icrucumab
imatinib mesilate
INCB-24360
inotuzumab ozogamicin
interferon
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
IPP-204106
irinotecan hydrochloride
ispinesib mesylate
JI-101
JX-594
kahalalide F
L19-IL2
Lambrolizumab
LEE-011
lenvatinib
LGX818
linifanib
LipoVIL12
LY-2275796
MDX-1379
MetXia
MGCD-265
MGN-1601
midostaurin
mitoxantrone
MKC-1106-MT
MORAb-004
motesanib diphosphate
muparfostat (IV)
NGR-TNF
nilotinib
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
OncoVAX
OTS-102
P276-00
paclitaxel
PancAtak
panobinostat
pazopanib hydrochloride
PCI-27483
pegdinetanib
peginterferon alfa-2b
perifosine
PF-4856884
pimasertib
pixantrone
plitidepsin
poly-ICLC
ponatinib
pralatrexate
ProstAtak
PTC-299
RAF-265
ramucirumab
razoxane
Reditux
regorafenib
retaspimycin
rhIFN-alpha
ridaforolimus
rintatolimod
rituximab
romidepsin
sagopilone
sargramostim
SCIB-1
selumetinib
sirolimus
sobuzoxane
sorafenib tosylate
SU-6668
sunitinib malate
talactoferrin alfa
talminogene laherparepvec
TAS-102
tasquinimod
TB-403
telatinib
temsirolimus
Tenarad
teniposide
tesetaxel
thalidomide
thymalfasin
tipifarnib
tivozanib
trabedersen
TRC-105
tremelimumab
vandetanib
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vismodegib
vitespen
volociximab
XL-184
XL-647
YM-155
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Melanoma and Angiogenesis.
    To find out more about Triple Analysis: Lymphoma, Melanoma and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Melanoma and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Lymphoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Antibodies. Learn More


Triple Analysis: Breast Cancer, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Learn More


Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. Learn More